BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. It is developing BARD1 lung cancer test, a screening test for the early detection of lung cancer in high-risk asymptomatic individuals; and BARD1 ovarian cancer test to detect ovarian cancer in high-risk women with a family history of breast/ovarian cancer or carrying BRCA1/2 mutations. The company has a collaboration with the Institute for Respiratory Health to evaluate a potential BARD1 cancer vaccine for the prevention and/or treatment of cancer in animal models. BARD1 Life Sciences Limited is based in South Perth, Australia.